Gilead Lures Roche Pharma CEO O'Day As CEO; Genentech's CEO Will Replace Him
Executive Summary
O'Day brings Gilead experience in oncology and M&A from a large, diversified organization.
You may also be interested in...
Gilead’s New O’Day Regime Has New R&D Structure
After several staff departures, Gilead consolidates its research arm under CEO oversight, while welcoming another Roche/Genentech alum.
With New Leadership, Roche Goes Back To Basics At ASCO
In a time of internal transition, Roche emphasized its deep roots and broad pipeline at its annual event alongside the American Society for Clinical Oncology meeting.
Gilead To Let Kite Fly Free; O’Day Says It Will Become Separate Business Unit
On his first earnings call, the new CEO said he wanted to make a quick decision on Kite, which will have its own CEO and autonomy. The unit's Yescarta posted 19% sequential revenue growth.